Symetis Seeks $60m IPO To Make A Splash In Structural Heart

21 Mar 2017

• By David Filmore

Symetis, Europe's No. 4 in the TAVR market, hopes its initial public offering, with a price range of €26 to €32 per share on Euronext Paris, will help build on its recent transcatheter mitral valve repair acquisition and its growing market position in TAVR.

Fresh off its entry into the mitral-valve repair space, Swiss firm Symetis SA is launching an initial public offering to support its plans to compete with big medtech firms in the structural heart market.

Symetis has been taking market share away from the likes of Edwards Lifesciences Corp. and Medtronic PLC in...